Cuprina closes IPO over-allotment, adding 648,373 shares on Nasdaq
What's the deal? Singapore-based biomedical company Cuprina Holdings (Cayman) LimitedDealroom has a profile for this one. Try Dealroom → (Nasdaq: CUPR) said it closed the sale of an additional 648,373 Class A ordinary shares. The shares were sold under the full exercise of its underwriter's over-allotment option, tied to the company's recent public offering. R. F. Lafferty & Co. acted as sole book-running manager.
What does Cuprina do? It develops and markets products across four sectors: chronic wounds, infertility, medical waste recycling, and cosmeceuticals. Its wound care products use materials from natural sources and are built as medical devices meeting international standards.
Why now? The offering follows Cuprina's Form F-1 registration statement, which the US Securities and Exchange Commission declared effective on September 15, 2026. The over-allotment closing marks the final step in the raise.
What's the endgame? Cuprina plans to use net proceeds to expand into new businesses and markets, fund R&D to broaden its product line, build brand awareness, and invest in equipment and infrastructure. The rest goes to working capital and general corporate purposes.
The signal: The Nasdaq listing gives a small Singapore biomedical firm access to US public markets, a route more Asian healthcare companies are taking to fund cross-border expansion.
Read more: marketscreener.com
Image credit: Generated with Gemini
